Searched for
BINO PATHIPARAMPIL
D-St breathes easy for a day as crude bucks rising trendThe Indian stock markets experienced a positive turn on Friday, bouncing back from a sharp drop earlier in the week, buoyed by decreasing o...- Indian generics wave next year set to sink obesity drug priceLeading Indian drugmakers are preparing to launch generic versions of semaglutide by March. Analysts predict a significant price drop, pote...
- Pharma exporters expect Trump to act benevolently to themIndian drug makers, heavily reliant on the US market, face potential challenges due to President Trump's proposed 25% reciprocal tariff on ...
- Sun Pharma’s baldness drug Leqselvi debuts in US market after patent dispute settledSun Pharmaceutical Industries has reached a settlement agreement with Incyte Corporation concerning Leqselvi, a drug for severe hair loss, ...
- Trump’s executive order on drug pricing could be a booster for Indian pharma industryDonald Trump's healthcare revamp, emphasizing generics and biosimilars, could boost Indian drug makers, who already supply 40% of US generi...
- Dr Reddy’s, Zydus, Cipla, Sun can sustain low-double digit EPS growth over medium term: Bino PathiparampilIndian pharma companies like Dr Reddy’s, Zydus, Cipla, and Sun can sustain low double-digit EPS growth over the medium term. The generic Re...
- Key market indices climb down from Trump TowerIndia's equity benchmarks fell on Thursday, driven by rising US bond yields and continued selling by foreign investors. The surge in US yie...
- Bino Pathiparampil expects positive momentum in pharma sector; has 3 top picksBino Pathiparampil of Elara Capital discussed the strong Q1 FY25 performance in the pharma sector. Companies like Lupin and Dr Reddy's rece...
- Modi’s Budget to send India’s soaring stocks higher: SurveyMore than half of the 24 respondents estimated that the Nifty 50 Index may advance up to 26,000 points by the end of 2024, while one predic...
- As of now, the risk of a major EPS downgrade for hospital stocks looks minimal: Elara CapitalThe Supreme Court has asked the government to regulate hospital charges, but the implementation of CGHS rates is uncertain. Private healthc...
- There is no risk to rally in smallcaps and broadcaps for now: Bino Pathiparampil, Elara Securities“We believe that flows will go more into relatively lower-valued stocks within the midcap and smallcap indices on a growth-adjusted basis. ...
- Should Daiichi Sankyo rechristen Ranbaxy?Daiichi Sankyo, the beleaguered Japanese owner of the drug maker, may be tempted to debate whether it is time to rechristen its Indian unit.
- No major under-performance seen in pharma sector: Bino Pathiparampil, IIFL"I would also look at Wockhardt which is in the midst of a rerating and the rerating process should continue for some time. "
- New drug pricing policy may affect Cadila & Cipla majorly: Bino Pathiparampil, IIFL"The new norms of the pharma pricing policy are a bit more stringent than the earlier norms that were put forward by the group of ministers...
- 10% upside to Ranbaxy if approval comes from USFDA: IIFLIn an interview with ET Now, Bino Pathiparampil, Analyst, Pharma, Institutional Equities, IIFL, talks about Ranbaxy. Excerpts:
- Ranbaxy struggling to get approvals for Lipitor; stock downShares of Ranbaxy were trading lower in early trade on Wednesday, following reports that the company is still struggling to get approvals f...
- Sun to stop making Alzheimer's drug after losing patent battleSun Pharma has lost patent battle for manufacturing and marketing of the generic version of Alzheimer's drug to US' Forest Laboratories.
- Lupin buys US rights of anti-cholesterol drug Antara for $39 mnLupin has bought the US marketing rights and inventory for cholesterol-lowering drug Antara from the bankrupt Oscient Pharma for $39 millio...
- GSK drug-deal talk lifts DRL scripShares of Dr Reddy’s Laboratories (DRL) touched an intra-day high of Rs 878.70, amid speculation that the Indian drug maker is in prelimina...
- Will swine flu be a boon for Indian generics?Tamiflu is not patent-protected in India and some other emerging markets, but it is in the US, Europe, and Mexico. Top 10 Drugmakers by sal...
Load More
